UNIVERSITY-OF-BOLTON
22.5.2020 12:23:11 CEST | Business Wire | Press release
The University of Bolton will introduce a range of innovative measures to ensure it can reopen its campus safely for students and staff in September.
It has released an animated video starring cartoon character ‘LearnEd the Owl’ which outlines in detail how the campus will be made Covid-19 secure in time for the new academic year.
Measures will include:
- Installing sophisticated airport style walk through temperature scanners at every building entry.
- Making bicycles available for loan by students, enabling them to avoid crowded public transport.
- Providing on-campus bike parks as well as car parks.
- Providing regular socially distanced face-to-face tutorials, laboratory experience, access to arts studios and specialist facilities, etc.
- Implementing an effective scheduling system, limiting significantly the number of students on campus at any one time to keep everyone secure.
- Dividing sessions for access on campus into set times per day, for example, possibly between 8am-2pm and 2pm-8pm.
- Strictly observing recommended social distancing guidelines at all times.
- Ensuring there are adequate additional sanitiser stations.
- Making the wearing of face coverings on campus compulsory for the foreseeable future to safeguard everyone’s safety. In exceptional circumstances, such as misplacing or forgetting face coverings, students and staff will be issued with replacements.
- Carefully managed walking routes including one-way navigation.
- Multiple ‘learning zones’ being created across the campus, by identifying and transforming large spaces into areas featuring tables with plastic dividing screens to allow communication between people facing one another. (E.g. The ground floor of the National Centre for Motorsport Engineering will be cleared to become such a zone and other areas will also be repurposed).
- Additional self-service, café-style takeaway food and drink stations to minimise queues.
- Instigating a rigorous cleansing programme throughout all university buildings.
Work is now underway on the adaptations, which are being carried out with the involvement of key academic and support staff.
Professor George E Holmes, President and Vice Chancellor of the University of Bolton, said: “From September we will provide a COVID Secure working and learning environment for students and staff.
“Students will have access to a fully operational University campus and be able to study and engage in person with other students and staff.
“This will mean widespread changes to create a ‘new normal’ on campus and enable all students to physically attend the University campus safely at specified sessions.
“During those sessions they will be able to work in laboratories, studios and workshops, attend tutorials, meet other students or converse with their tutor, on top of continuing their learning online.”
Prof Holmes said: “I am determined that the University of Bolton is ahead of the game in transforming its campus to create a place where our students feel safe and happy and can make the most of their experience of Higher Education.
“The University student experience is not just about learning. Students want to see their friends in person, they want to engage with their tutors.
“Under our plans we can ensure they will be able to do this safely in September.”
The animated video outlining the University of Bolton safety measures under the ‘new normal’ can be watched at: https://youtu.be/yJKuGwVls7M
Ends
Notes to Editors:
Images (via We Transfer): Professor George E Holmes, President and Vice Chancellor of the University of Bolton; plus still images from the video and stock images of the UoB campus.
Link: https://we.tl/t-qcZUtcNwEw
View source version on businesswire.com: https://www.businesswire.com/news/home/20200522005146/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
